drugset / Trial / NCT00743938
A Comparison Between BMS-690514 and Erlotinib in Patients Who Were Previously Treated for NSCLC
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to improve disease control and survival for patients who were treated with chemotherapy using BMS-690514 over erlotinib
Timeline
- Start
- 2009-03
- Primary completion
- 2010-08
- Completion
- 2012-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BMS-690514 | Small molecule | 200 mg | Oral |
| Comparator | Erlotinib | Small molecule | 150 mg | Oral |